SCHEMBL256337

SCHEMBL256337

Cn1cnc2cnccc21

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FGFR1 P11362 1/20 0.53
NAMPT P43490 1/20 0.43
ALDH1A1 P00352 4/20 0.42
KDM4E B2RXH2 2/20 0.42
GLA P06280 1/20 0.42
GAA P10253 1/20 0.42
TSHR P16473 1/20 0.42
ATM Q13315 1/20 0.42
LTA4H P09960 1/20 0.41
GRM5 P41594 1/20 0.41
MAPT P10636 3/20 0.40
NPC1 O15118 2/20 0.39
TP53 P04637 2/20 0.39
RAB9A P51151 2/20 0.39
LMNA P02545 1/20 0.39
HPGD P15428 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
HSD17B10 Q99714 1/20 0.39
JAK2 O60674 1/20 0.38
JAK3 P52333 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29593970 1.00 FGFR1 (0.53) FGFR1NAMPTALDH1A1KDM4EGLA
SCHEMBL8659170 0.85 FGFR1 (0.45) FGFR1NAMPTALDH1A1KDM4EGLA
SCHEMBL84793 0.83 LTA4H (0.41) FGFR1NAMPTALDH1A1KDM4EGLA
SCHEMBL12801974 0.76 LTA4H (0.52) FGFR1ALDH1A1KDM4ELTA4HMAPT
SCHEMBL25291568 0.75 FGFR1 (0.53) FGFR1ALDH1A1KDM4EATMLTA4H
SCHEMBL18330920 0.75 FGFR1 (0.53) FGFR1ALDH1A1KDM4EATMLTA4H
SCHEMBL4059255 0.75 FGFR1 (0.53) FGFR1ALDH1A1KDM4EATMLTA4H
SCHEMBL4448529 0.75 FGFR1 (0.53) FGFR1ALDH1A1KDM4EATMLTA4H
SCHEMBL1106481 0.75 FGFR1 (0.49) FGFR1ALDH1A1KDM4EGAAATM
SCHEMBL29808177 0.75 KDM4E (0.51) FGFR1ALDH1A1KDM4EGAALTA4H

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 198 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12552811-B2 Immunosuppressant, and preparation method therefor and use thereof ABBISKO THERAPEUTICS CO., LTD. (CN) 2026-02-17 US disclosed
US-12473282-B2 Biphenyl fluorine double bond derivative, preparation method therefor, and pharmaceutical application thereof ABBISKO THERAPEUTICS CO., LTD. (CN) 2025-11-18 US disclosed
EP-3801499-B1 INHIBITORS OF SARM1 DISARM THERAPEUTICS INC (US) 2024-02-28 EP disclosed
US-20230303613-A1 3′3′ CYCLIC DINUCLEOTIDES WITH AN ALKENYLENE INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY AS CR, V.V.I. (CZ) 2023-09-28 US disclosed
EP-3445762-B1 SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS BRISTOL MYERS SQUIBB CO (US) 2023-09-13 EP disclosed
CN-114502556-B Biphenyl fluoro double bond derivative, preparation method thereof and application thereof in pharmacy 上海和誉生物医药科技有限公司 2023-07-28 CN disclosed
US-20230234970-A1 IMMUNOSUPPRESSANT, AND PREPARATION METHOD THEREFOR AND USE THEREOF ABBISKO THERAPEUTICS CO., LTD. (CN) 2023-07-27 US disclosed
US-20230234970-A1 IMMUNOSUPPRESSANT, AND PREPARATION METHOD THEREFOR AND USE THEREOF ABBISKO THERAPEUTICS CO., LTD. (CN) 2023-07-27 US disclosed
US-20230234970-A1 IMMUNOSUPPRESSANT, AND PREPARATION METHOD THEREFOR AND USE THEREOF ABBISKO THERAPEUTICS CO., LTD. (CN) 2023-07-27 US disclosed
US-20230149560-A1 LIPID COMPOSITIONS FOR DELIVERY OF STING AGONIST COMPOUNDS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. 2023-05-18 US disclosed
US-20070021442-A1 HIV reverse transcriptase inhibitors MERCK SHARP & DOHME CORP. 2007-01-25 US disclosed
WO-2006089909-A1 NOVEL ANTITHROMBOTIC SUBSTITUTED PYRROLIDINONES, THE PRODUCTION AND USE THEREOF IN THE FORM OF MEDICAMENTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2006-08-31 WO disclosed
EP-1134222-B1 IMIDAZO[4,5-b]PYRIDINIUMMETHYL-CONTAINING CEPHEM COMPOUNDS HAVING BROAD ANTIBACTERIAL SPECTRUM SHIONOGI & CO (JP) 2005-04-13 EP disclosed
US-6800621-B2 FOR THERAPY AND PROPHYLAXIS OF BACTERIAL INFECTIOUS DISEASES SHIONOGI & CO., LTD. (JP) 2004-10-05 US disclosed
US-20030149014-A1 Imidazo[4,5-b]-pyridinium-containing cephem compounds having broad antibacterial spectrum activity SHIONOGI & CO., LTD. 2003-08-07 US disclosed
US-6518263-B1 Imidazo[4,5-b]pyridiniummethyl-containing cephem compounds having broad antibacterial spectrum SHIONOGI & CO., LTD. (JP) 2003-02-11 US disclosed
EP-1134222-A1 IMIDAZO[4,5-b]PYRIDINIUMMETHYL-CONTAINING CEPHEM COMPOUNDS HAVING BROAD ANTIBACTERIAL SPECTRUM SHIONOGI & CO., LTD. (JP) 2001-09-19 EP disclosed
US-4748172-A 3-bicyclicpyridinium-methyl cephalosporins ELI LILLY AND COMPANY (US) 1988-05-31 US disclosed
US-4692443-A 3-bicyclicpyridinium-methyl cephalosporins ELI LILLY AND COMPANY (US) 1987-09-08 US disclosed
EP-0138552-A2 Improvements on or relating to 3-bicyclicpyridinium-methyl cephalosporins ELI LILLY AND COMPANY (US) 1985-04-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230149560-A1 LIPID COMPOSITIONS FOR DELIVERY OF STING AGONIST COMPOUNDS AND USES THEREOF STING1, CGAS, TLR9 FGFR1 3910/4885NAMPT 2448/4885ALDH1A1 4863/4885
US-12552811-B2 Immunosuppressant, and preparation method therefor and use thereof CD274, PDCD1, PDCD1LG2 FGFR1 714/4885NAMPT 2544/4885ALDH1A1 341/4885
US-20070021442-A1 HIV reverse transcriptase inhibitors POLRMT, RNGTT, POLR2E FGFR1 4826/4885NAMPT 249/4885ALDH1A1 2363/4885
US-12473282-B2 Biphenyl fluorine double bond derivative, preparation method therefor, and pharmaceutical application thereof PDCD1, CD274, PDCD1LG2 FGFR1 11/4885NAMPT 1828/4885ALDH1A1 171/4885
US-20230234970-A1 IMMUNOSUPPRESSANT, AND PREPARATION METHOD THEREFOR AND USE THEREOF CD274, PDCD1, PDCD1LG2 FGFR1 407/4885NAMPT 582/4885ALDH1A1 106/4885
US-20030149014-A1 Imidazo[4,5-b]-pyridinium-containing cephem compounds having broad antibacterial spectrum activity CCNY, LBR, B2M FGFR1 3233/4885NAMPT 3807/4885ALDH1A1 4005/4885
US-20230303613-A1 3′3′ CYCLIC DINUCLEOTIDES WITH AN ALKENYLENE STING1, CGAS, IRF3 FGFR1 3789/4885NAMPT 534/4885ALDH1A1 3968/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.